Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease Aug 29, 2021
Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson’s Disease Clinical Study Allowing for At-Home Titration Aug 15, 2021
Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease Aug 12, 2021
Cynapsus Therapeutics Reports Second Quarter 2016 Financial Results and Recent Developments Aug 10, 2021
Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease Jul 18, 2022
Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease Jul 18, 2022
Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease Jun 30, 2022
Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders Jun 21, 2022
